Keel Point’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.46M | Sell |
2,671
-1,414
| -35% | -$1.43M | 0.16% | 90 |
|
|
2025
Q4 | $4.39M | Buy |
4,085
+476
| +13% | +$455K | 0.26% | 59 |
|
|
2025
Q3 | $2.75M | Buy |
3,609
+21
| +0.6% | +$15.6K | 0.17% | 91 |
|
|
2025
Q2 | $2.8M | Buy |
3,588
+55
| +2% | +$42.7K | 0.18% | 86 |
|
|
2025
Q1 | $2.92M | Buy |
3,533
+532
| +18% | +$443K | 0.23% | 81 |
|
|
2024
Q4 | $2.32M | Buy |
3,001
+104
| +4% | +$86.1K | 0.19% | 88 |
|
|
2024
Q3 | $2.57M | Sell |
2,897
-122
| -4% | -$110K | 0.21% | 82 |
|
|
2024
Q2 | $2.74M | Buy |
3,019
+793
| +36% | +$634K | 0.25% | 72 |
|
|
2024
Q1 | $1.73M | Buy |
2,226
+166
| +8% | +$118K | 0.18% | 90 |
|
|
2023
Q4 | $1.2M | Buy |
2,060
+49
| +2% | +$28.6K | 0.14% | 103 |
|
|
2023
Q3 | $1.08M | Buy |
2,011
+30
| +2% | +$15.5K | 0.15% | 100 |
|
|
2023
Q2 | $929K | Buy |
1,981
+136
| +7% | +$57K | 0.12% | 112 |
|
|
2023
Q1 | $634K | Sell |
1,845
-26
| -1% | -$8.77K | 0.09% | 137 |
|
|
2022
Q4 | $685K | Buy |
1,871
+172
| +10% | +$61K | 0.11% | 131 |
|
|
2022
Q3 | $549K | Buy |
1,699
+12
| +0.7% | +$3.8K | 0.09% | 134 |
|
|
2022
Q2 | $514K | Sell |
1,687
-142
| -8% | -$42.6K | 0.08% | 141 |
|
|
2022
Q1 | $524K | Sell |
1,829
-5
| -0.3% | -$1.29K | 0.08% | 144 |
|
|
2021
Q4 | $507K | Sell |
1,834
-107
| -6% | -$27.1K | 0.06% | 150 |
|
|
2021
Q3 | $448K | Buy |
1,941
+439
| +29% | +$108K | 0.06% | 158 |
|
|
2021
Q2 | $345K | Buy |
1,502
+4
| +0.3% | +$803 | 0.04% | 183 |
|
|
2021
Q1 | $280K | Buy |
1,498
+233
| +18% | +$45.6K | 0.03% | 210 |
|
|
2020
Q4 | $214K | Sell |
1,265
-134
| -10% | -$20K | 0.02% | 228 |
|
|
2020
Q3 | $207K | Buy |
+1,399
| New | +$217K | 0.02% | 207 |
|
|
2019
Q1 | – | Sell |
-5,190
| Closed | -$601K | – | 208 |
|
|
2018
Q4 | $601K | Hold |
5,190
| – | – | 0.08% | 102 |
|
|
2018
Q3 | $557K | Buy |
5,190
+514
| +11% | +$51.4K | 0.07% | 93 |
|
|
2018
Q2 | $399K | Sell |
4,676
-2,100
| -31% | -$172K | 0.05% | 104 |
|
|
2018
Q1 | $524K | Sell |
6,776
-789
| -10% | -$63.5K | 0.07% | 88 |
|
|
2017
Q4 | $639K | Sell |
7,565
-200
| -3% | -$17K | 0.09% | 79 |
|
|
2017
Q3 | $664K | Hold |
7,765
| – | – | 0.1% | 78 |
|
|
2017
Q2 | $639K | Buy |
7,765
+200
| +3% | +$16.3K | 0.13% | 79 |
|
|
2017
Q1 | $636K | Hold |
7,565
| – | – | 0.13% | 78 |
|
|
2016
Q4 | $556K | Buy |
7,565
+705
| +10% | +$52.5K | 0.12% | 78 |
|
|
2016
Q3 | $551K | Hold |
6,860
| – | – | 0.21% | 70 |
|
|
2016
Q2 | $540K | Buy |
6,860
+1,521
| +28% | +$115K | 0.23% | 73 |
|
|
2016
Q1 | $384K | Buy |
5,339
+66
| +1% | +$4.99K | 0.19% | 89 |
|
|
2015
Q4 | $444K | Buy |
5,273
+185
| +4% | +$15.4K | 0.24% | 80 |
|
|
2015
Q3 | $426K | Buy |
5,088
+470
| +10% | +$39.7K | 0.24% | 70 |
|
|
2015
Q2 | $382K | Buy |
4,618
+547
| +13% | +$41.7K | 0.18% | 70 |
|
|
2015
Q1 | $296K | Buy |
+4,071
| New | +$290K | 0.15% | 75 |
|
Other funds holding LLY
VCM
VPM
Keel Point's LLY Position: Q1 2026 in Review
Keel Point reduced its Eli Lilly (LLY) stake by 35% in Q1 2026, selling an estimated $1.43M and leaving 2,671 shares worth $2.46M. The position accounts for 0.16% of the portfolio, ranked #90.
Keel Point first reported a position in LLY in Q1 2015 and has held it in 39 quarters since. The position peaked at $4.39M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Keel Point held 2,671 shares of Eli Lilly worth $2.46M as of Q1 2026.
- Keel Point sold 1,414 Eli Lilly shares in Q1 2026, an estimated $1.43M.
- Eli Lilly made up 0.16% of Keel Point's portfolio in Q1 2026, its #90 holding.
- Keel Point first reported a position in Eli Lilly in Q1 2015 and has held it in 39 quarters since.
- Keel Point's Eli Lilly position peaked at $4.39M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.